Social Trust — The Condition for This Industry to Exist— The economics of trust around a good that cannot be verified

01A product where "trust" is the market's precondition

For food, taste tells you. For appliances, you can test. For clothes, you try them on. Most products let the buyer check quality with their own senses. That is where ordinary markets start.

Medicine is different. Looking at the tablet tells you nothing about efficacy. By the time you feel "it worked" or "I had a side effect", you have already taken it. There is, essentially, no way to verify in advance. That is what makes pharmaceuticals a peculiar good.

So why does the patient take it? Because they trust the doctor's prescription; the doctor trusts the trial data; the trial data trusts the regulator that audits it; the regulator trusts the government that built it; and underneath all of that, everyone trusts that the pharma company has honestly submitted its data. A long chain of trust holding up trust.

02Search, experience, credence goods — the economics frame

Economics distinguishes three kinds of goods. Nelson (1970), Darby & Karni (1973).

Medicine is a classic credence good. Even after taking it, the patient cannot disentangle drug effect from natural healing or placebo. If a side effect appears, attributing it to the drug versus other causes needs expert judgment. The very impossibility of verification puts the quality of trust itself at the heart of the transaction.

03Pharma is the far end of credence goods

Even among credence goods, restaurant food and medicine carry different weights of trust. A bad meal upsets your stomach. A bad drug decision can cost a life. So pharma sits at the heaviest end of the credence-good spectrum.

Three asymmetries run extreme.

When the three asymmetries overlap, the patient is left with "trust, or nothing". The structure itself creates ethical obligation on the pharma side.

04What happens when trust breaks

If trust is the market's precondition, then a broken trust is a broken market. History has shown this repeatedly.

• Thalidomide (1957–1962): sold with insufficient safety data for pregnant women; over 10,000 severe-birth-defect cases worldwide. The premise that "pharma verifies pregnancy safety in-house" collapsed, triggering structural reform of pharmaceutical law
• HIV blood-products disaster (Japan, 1980s): continued sale of unheated blood products after danger was known; 1,500+ victims. The premise "once danger is recognized, the company withdraws" collapsed, leading to litigation and strengthened pharmaceutical law
• Vioxx (Merck, 1999–2004): cardiovascular-risk data not published for years; tens of thousands of MI/death cases. The premise "the company publishes inconvenient data too" collapsed; FDA post-market surveillance was transformed
• Diovan (Japan, 2014): pharma staff improperly intervened in university clinical-research data. The premise "company and research are independent" collapsed; COI disclosure became dramatically stricter

The common thread is that "the incident itself" matters less than the spillover to the whole industry. One company's dishonesty erodes industry-wide trust, tightens regulation, raises costs for everyone, and slows the speed at which patients can access new drugs. Broken trust burns a shared asset of the whole industry.

05Four layers that hold trust up

Why does this fragile trust hold in real markets? Society has supported it in four layers.

What is interesting: as you go from Layer 1 down to Layer 4, enforceability weakens, but reach widens. Regulation is strong but coarse for the individual case. Individual ethics has zero enforceability but touches every small daily decision.

The four layers are complements. Regulation alone cannot reach the detail. Self-regulation alone cannot bind firms. Corporate governance alone cannot bind individuals. Individual ethics alone cannot change an organization. Only when all four are in place does trust actually hold.

06Individual × Organization × Industry — trust is accumulated

Trust does not spring up from an organization automatically. It is the integration of specific actions.

At the individual level: each person's honest statement, honest record, honest report — these build trust in that person. An MR conveying data accurately, a researcher publishing inconvenient results, a marketer avoiding exaggeration in promotional materials — the integral of these is trust in the organization.

At the organizational level: consistency across the whole firm. "Leadership says clean, but the field cooks numbers" — that does not build organizational trust. "Word matches deed" is the touchstone at this level. Are leadership's statements, on-the-ground metrics, and the evaluation system all pointing the same direction?

At the industry level: discipline beyond any single firm. The JPMA Code is a compact between competitors that says "this far, we all observe". If one of your competitors breaks it, the whole industry pays. So industry self-regulation carries a cooperative aspect among competitors.

The three levels reinforce each other. Individual honesty builds the organization; organizational honesty builds the industry; industry discipline narrows the individual's room to slip. The reverse runs the same way: an industry's rot bends organizational judgment, and organizational rot bends individual judgment. The accumulation of trust is a two-way loop.

07Trust in the SNS era — one dishonest act spreads instantly

Once, getting a dishonest act to the public required newspapers or TV reporting. Not anymore. A patient's single SNS post can reach a million views in hours. The economics of trust changed.

Three shifts:

• Damage moves orders of magnitude faster: one dishonest act can become industry-wide distrust within 24 hours
• Repair speed has not changed: damage is instant; repair takes years. The asymmetry between damage and repair speeds has become extreme
• Industry-wide spillover: one firm's incident now translates directly to distrust of the industry as a category. Patients see "pharma" as one category

What this means is that "small honesties in peacetime" matter more than ever. Apologizing after an incident is no longer enough. The integral of countless small daily choices, before any incident, is what becomes the trust reserve when something goes wrong.

08Implementing honesty — the integral of small decisions

"Trust" and "honesty" are abstract. Translated into ground-level behavior in pharma's daily work, honesty shows up as small decisions like these.

• MR information delivery: present the disadvantaged points at the same temperature as the advantaged ones
• Publication: publish trials that didn't show the expected result, too (avoiding publication bias)
• Materials: don't cut chart axes favorably; don't distort the context of citations; don't cherry-pick comparators
• Post-market safety: don't delay AE reports; don't downplay severity
• Internal reporting: relay information unfavorable to the boss, unedited
• Regulatory interactions: don't hide what you don't want seen during audits and inspections
• Research relationships: don't compromise independence with academic researchers (the Diovan lesson)

Each is a small decision. Every one of them comes with the temptation of "just this once". But the integral of those small decisions becomes the organization's culture and the industry's trust. The integral of small decisions is the total volume of social trust.

09Application in pharma

How to land this in tomorrow's work? Three habits.

1. The habit of noticing "this work involves a credence good" — the data, documents, and outputs you touch are a mass of information the patient cannot verify. Precisely because it is unverifiable, the weight of your honesty is heavier here than in other industries
2. The habit of asking "what would this look like on SNS?" — before deciding, picture how the act would read through the patient's eyes. Dishonest acts no longer stay internal
3. The habit of asking "does this add to or subtract from trust savings?" — before each decision, think about how it affects the organization's and the industry's trust reserve. The question aligns small choices in a coherent direction

All three sound abstract. But making the habit of asking even one second a day shifts the direction of judgment. Holding "why we keep the rules" makes the same rules operate to different results, in people who hold it and people who do not.

10Into the next volume

This piece organized "why trust is needed, what happens when trust breaks, and the four-layer system that supports it". Vol. 3 will turn to the first of the four corporate pillars: corporate philosophy.

Corporate philosophy is not decoration or framed text. It is what the field returns to in a crisis, when judgment runs out. With a philosophy, decisions align even where no guideline reaches. Without one, rules become formalism and the field gets carried by numbers. Vol. 3 will work through real examples of how that operates.